CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 522 enrolled
Drug / intervention
recombinant human erythropoietin alfa +1 moredrug
Likely dose
recombinant human erythropoietin alfa 40,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00604630
NCT00604630Phase 3Completed
CompareCT.gov

German Multicenter EPO Stroke Trial (Phase II/III)

Max-Planck-Institute of Experimental Medicine·interventional·Posted Jan 30, 2008·Updated Oct 22, 2008

In Brief

A Phase 3 clinical trial evaluating recombinant human erythropoietin alfa and 0.9% NaCl for Infarction, Middle Cerebral Artery and 2 related conditions. Completed, enrolled 522 participants across 9 sites.

Detailed Summary

The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke, Stroke, Acute
CountriesGermany
CollaboratorsJohnson & Johnson, Parexel

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2008
Enrollment StartJan 1, 2003
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 18.4 years ago

Interventions

recombinant human erythropoietin alfadrug

40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms

0.9% NaCldrug

50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms